N. Scharenborg

发表

Endothelial cell seeding of (heparinized) collagen matrices: effects of bFGF pre-loading on proliferation (after low density seeding) and pro-coagulant factors.

J. Feijen, A. Poot, T. Beugeling, 2000, Journal of controlled release : official journal of the Controlled Release Society.

Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.

W. Oyen, C. Figdor, C. Punt, 2003, Cancer research.

Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.

C. Figdor, C. Punt, D. Ruiter, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phenotypical and functional characterization of clinical-grade dendritic cells.

C. Figdor, C. Punt, G. Adema, 2005, Methods in molecular medicine.

The Dendritic Cell-Specific CC-Chemokine DC-CK1 Is Expressed by Germinal Center Dendritic Cells and Attracts CD38-Negative Mantle Zone B Lymphocytes

C. Figdor, G. Adema, R. Huijbens, 2001, The Journal of Immunology.

Mantle Zone B Lymphocytes Dendritic Cells and Attracts CD 38-Negative DC-CK 1 Is Expressed by Germinal Center The Dendritic Cell-Specific CC-Chemokine Figdor

G. Adema, R. Huijbens, F. Hartgers, 2001 .

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity

W. Oyen, C. Figdor, C. Punt, 2016, Cancer Immunology, Immunotherapy.

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

C. Figdor, C. Punt, C. Blank, 2015, Clinical Cancer Research.

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients

C. Figdor, C. Punt, J. D. de Wilt, 2016, Oncoimmunology.

Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.

C. Figdor, C. Punt, D. Ruiter, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

W. Oyen, C. Figdor, C. Punt, 2011, Clinical Cancer Research.

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

C. Figdor, C. Punt, P. Coulie, 2010, Cancer Immunology, Immunotherapy.

Advances in Brief Effective Migration of Antigen-pulsed Dendritic Cells to Lymph Nodes in Melanoma Patients Is Determined by Their Maturation State 1 , 2

W. Oyen, C. Figdor, C. Punt, 2002 .

Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.

C. Figdor, C. Punt, G. Adema, 2010, Anticancer research.

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients

C. Figdor, C. Punt, B. Neyns, 2015, Oncoimmunology.

Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests.

C. Figdor, T. Ruers, C. Punt, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

C. Figdor, C. Punt, G. Adema, 2010, Clinical Cancer Research.

MR tracking of magnetically-labeled dendritic cells migrating to lymph nodes in melanoma patients: First clinical experience

W. Oyen, T. Scheenen, J. Bulte, 2005 .

Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration

C. Figdor, C. Punt, G. Adema, 2008, Cancer Immunology, Immunotherapy.

Proliferation of endothelial cells on surface-immobilized albumin-heparin conjugate loaded with basic fibroblast growth factor.

J. Feijen, A. Poot, T. Beugeling, 1999, Journal of biomedical materials research.

Blood compatibility of surfaces with immobilized albumin-heparin conjugate and effect of endothelial cell seeding on platelet adhesion.

J. Feijen, A. Poot, T. Beugeling, 1999, Journal of biomedical materials research.

Endothelialization of Crosslinked Albumin-heparin Gels

J. Feijen, A. Poot, T. Beugeling, 1999, Thrombosis and Haemostasis.

Adherence and proliferation of endothelial cells on surface-immobilized albumin-heparin conjugate.

J. Feijen, A. Poot, T. Beugeling, 1998, Tissue engineering.

Clinical Cancer esearch cer Therapy : Clinical dritic Cell Vaccination in Combination with Anti-CD 25 oclonal Antibody Treatment : A Phase I / II Study in R astatic Melanoma Patients

C. Punt, L. Hilbrands, I. Klasen, 2010 .

Development of 111In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination.

W. Oyen, C. Figdor, G. Adema, 2006, Nuclear medicine and biology.

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients

C. Figdor, C. Punt, G. Adema, 2010, British Journal of Cancer.

Renal cell carcinoma–associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen‐dr molecules to CD4+ T lymphocytes

C. Figdor, G. Adema, E. Oosterwijk, 2002, International journal of cancer.

In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients

C. Figdor, C. Punt, G. Adema, 2007, Cancer Immunology, Immunotherapy.

Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines

T. Scheenen, J. Bulte, C. Figdor, 2006, International journal of cancer.

Phenotypical and Functional Characterization of Clinical Grade Dendritic Cells

C. Figdor, C. Punt, G. Adema, 2002, Journal of immunotherapy.

Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration

C. Figdor, C. Punt, G. Adema, 2008, Cancer Immunology, Immunotherapy.

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Inge M. N. Wortel, J. Bonenkamp, W. Gerritsen, 2024, Nature communications.